FDA Clearance Tracker · P970043-S007
LADAR VISION EXCIMER LASER SYSTEM (HYPEROPIA)
Last checked: Nov 20, 2026Latest source record: Sep 22, 2000 (this decision)Source: openFDAMethods & limitations
Decided
Sep 22, 2000
Approved
Time to decision
385 days
Received Sep 3, 1999. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P970043-S007
- Device name
- LADAR VISION EXCIMER LASER SYSTEM (HYPEROPIA)
- Applicant
- Alcon Laboratories
- Applicant location
- Fort Worth, TX
- Received
- Sep 3, 1999
- Decided
- Sep 22, 2000
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Expedited review
- Yes, flagged as expedited in FDA's record.
- Original approval
- P970043
Device type
- Device type
- Excimer laser system (LZS)
- Device class
- Class III
- Specialty
- Ophthalmology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR THE LADARVISION(R) EXCIMER LASER SYSTEM. THE DEVICE IS INDICATED FOR LASER IN-SITU KERATOMILEUSIS (LASIK) TREATMENTS: 1) FOR THE REDUCTION OR ELIMINATINO OF REFRACTIVE ERROR OF LESS THAN OR EQUAL TO +6.00D OF SPHERE AND -6.00D OF CYLINDER AT THE SPECTACLE PLANE (HYPEROPIA WITH OR WITHOUT ASTIGMATISM AND MIXED ASTIGMATISM); 1) IN SUBJECTS WITH DOCUMENTED STABILITY OF REFRACTION FOR THE PRIOR 12 MONTHS, AS DEMONSTRATED BY A CHANGE OF LESS THAN OR EQUAL TO 0.50D FOR CORRECTIONS UP TO +6.00D SE; AND, 3) IN SUBJECTS WHO ARE 21 YEARS OF AGE OR OLDER.
Source documents
Other decisions for Alcon Laboratories
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K254052 · Decided Feb 13, 2026 · 58 days after receipt
Device type: Lenses, Soft Contact, Daily Wear (LPL) · Ophthalmology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.